started · updated
US Department of Health and Human Services adjusts medical regulations
The US Department of Health and Human Services (HHS), led by Robert F. Kennedy Jr., has implemented two significant shifts in medical regulation.
First, the Food and Drug Administration (FDA) has removed Black Box warnings from three estradiol transdermal patches: Minivelle, Vivelle, and Vivelle-Dot. These products are used to treat menopause symptoms such as hot flashes and sleep disturbances. The removed warnings previously cited increased risks of cardiovascular disease, potential dementia, and breast cancer. The FDA stated the decision follows a re-evaluation of scientific data, noting that the previous warnings were based on the Women’s Health Initiative study from the early 2000s, which focused on older demographics.
Second, the HHS has suspended legal action against pharmacies manufacturing and selling six unapproved peptides, including BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. The administration argues this move aims to steer patients away from unregulated black markets toward safer, monitored channels. However, medical professionals have expressed concern regarding the lack of human clinical data for these substances. Dr. Shiloah Kviatkovsky of the University of Arkansas for Medical Sciences noted that the market is currently outpacing research, with clinical studies for some substances not expected until 2027.
Entities
Food and Drug Administration · Robert F. Kennedy Jr. · U.S. Department of Health and Human Services · U.S. Food and Drug Administration · US Department of Health and Human Services · University of Arkansas for Medical Sciences